Clinical Trials Browser

Phase 3 × OTHER × nilotinib × Clear all

NCT02201459 2025-10-02

PETALs

Phase 3 Completed

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02326311 2024-08-13

Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response

Phase 3 Completed

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01657604 2023-05-10

TIGER

Phase 3 Completed

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03942094 2022-03-16

Nilotinib for First-line Newly Diagnosed CML-CP Patients

Phase 3 Unknown

Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase

NCT02174445 2019-12-02

DECLINE

Phase 3 Terminated

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01535391 2018-08-06

CML0811

Phase 3 Completed

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01400074 2014-01-13

RE-NICE

Phase 3 Unknown

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01819389 2014-01-07

Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance

Phase 3 Completed

MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive